A recent study suggests that people who discontinue new slimming jabs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who end conventional lifestyle regimens.
Research printed in a prominent health publication points out that while obese individuals often shed about a fifth of their body weight while using the jabs, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals buying such medications should be cognizant of the potential of rapid rebound weight gain when the treatment ends," warns expert Dr. Susan Jebb.
Such speed of recovery implies a return to pre-treatment mass within about 18 months.
Weighing Treatments
The analysis, which looked at 37 of studies involving thousands of participants, contrasted the outcomes of these new drugs with conventional dieting.
The team emphasize that people who lose weight through diet and exercise usually see a less rapid weight regain—approximately 0.1 kg a month—once they finish.
Explaining the Rapid Regain
Experts suggest the way of the jabs accounts for the heightened rebound.
The injections mimic a body's own chemical called GLP-1, which helps regulate appetite.
"Long-term administration of the hormone concentrations several times higher than normal may cause the body to generate a reduced amount of its endogenous hormone, and could reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement leads to appetite is uncontrolled, making binge eating far more likely."
A Chronic Issue?
Health authorities suggest the jabs for people with weight-linked health risks, alongside prescribed diet and exercise modifications.
Many experts say that, considering the likelihood of weight regain, the treatment might need to be long-term.
This opinion is supported by drug manufacturers, who say that the results "underscore the persistent character of obesity," akin to managing conditions like high blood pressure.
User Testimonies
People who have discontinued the medication report a powerful resurgence of cravings.
"It was like something activating and you become ravenous," described a patient.
The struggle is worsened if users have not established sustainable lifestyle or habit changes during treatment.
Significant Adoption
Recent estimates show that millions of adults in the UK have used these injections in the last 12 months, with interest being substantial.
- Adoption is more common among females compared to men.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, researchers caution that while GLP-1 drugs are powerful tools for weight loss, they are not a magic fix and long-term success hinges on ongoing behavioural management.
